Clinical experience with romiplostim
Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refra...
Main Authors: | G. B. Kuchma, L. K. Kozlova, Ye. Ye. Kuznetsova, S. B. Borisyuk |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2014-07-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/10 |
Similar Items
-
Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01) -
Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
by: Efthymia Vlachaki, et al.
Published: (2011-10-01) -
Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description
by: Rodriguez Nuñez Rosa María, et al.
Published: (2020-04-01) -
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
by: Francesca Palandri, et al.
Published: (2012-06-01) -
Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
by: Cy R. Wilkins, et al.
Published: (2022-03-01)